DNA CONTENT IN CERVICAL-CARCINOMA - A FLOW CYTOMETRIC ASSESSMENT OF DNA HETEROGENEITY
DNA CONTENT IN CERVICAL-CARCINOMA - A FLOW CYTOMETRIC ASSESSMENT OF DNA HETEROGENEITY
复制标题
DOI：
10.1097/00004347-199410000-00006
复制
发表时间：
1994-10-01
影响因子：
2.4
通讯作者：
KIRK, ME
中科院分区：
文献类型：
--
作者：
CHANG, AR;GRIGNON, DJ;KIRK, ME
DNA异质性的程度在不同身体部位发生的肿瘤之间变化。任何实质性程度的变化，在一个给定的肿瘤可以引起显着的问题，在解释DNA流式细胞术（FCM）研究。本研究旨在探讨宫颈癌DNA异质性的程度。共100个3毫米打孔活检进行了评价，从单一的大型案件在10个部分的宫颈癌。10例肿瘤中，6例为鳞癌，1例为腺癌，1例为小细胞和鳞癌混合型，1例为腺鳞癌，1例为小细胞癌伴小面积腺癌。95份（95%）样本可获得适当的直方图。在研究的10例中，9例（90%）显示DNA模式的同质性。一个孤立的情况下，表现出异质性在一个直方图（9个样本DNA二倍体和一个样本DNA非整倍体）。该病例主要为小细胞未分化癌伴局灶性腺癌。腺癌区域可能是导致FCM模式异质性的区域。从这项研究中，我们得出结论，对于大多数宫颈癌的一个特定的组织学类型有DNA同质性。然而，对于具有混合形态的癌，DNA异质性是可能的，并且在包括混合或组合肿瘤的任何DNA倍性研究中必须考虑到这一点。
The degree of DNA heterogeneity varies between tumors arising in different body sites. Any substantial degree of variability within a given tumor can give rise to significant problems in the interpretation of DNA flow cytometric (FCM) studies. This study was undertaken to evaluate the degree of DNA heterogeneity in cervical carcinomas. A total of 100 3-mm punch biopsies were evaluated from single large cases in 10 sections of cervical carcinoma. Of the 10 tumors, 6 were squamous carcinoma, 1 was an adenocarcinoma, 1 was a mixed small cell and squamous carcinoma, 1 was an adenosquamous cancer, and I was a small cell carcinoma with a small area of adenocarcinoma. Adequate histograms were available for 95 (95%) of the samples. Of the 10 cases studied, 9 (90%) revealed homogeneity in the DNA pattern. A solitary case demonstrated heterogeneity in one histogram (nine samples DNA diploid and one sample DNA aneuploid). This case was predominantly small cell undifferentiated carcinoma with focal adenocarcinoma. The area of adenocarcinoma was probably the area that contributed to the heterogeneous FCM pattern. From this study we conclude that for most cervical carcinomas of a specific histologic type there is DNA homogeneity. However, for carcinomas with a mixed morphology, DNA heterogeneity is possible and this must be taken into account in any DNA ploidy studies that include mixed or combined tumors.